Featured Research

from universities, journals, and other organizations

Statin may slow untreatable, progressive stage of multiple sclerosis

Date:
March 18, 2014
Source:
The Lancet
Summary:
Simvastatin, a cheap cholesterol lowering drug, might be a potential treatment option for the secondary progressive, or chronic, stage of multiple sclerosis, which is currently untreatable, results of a phase 2 study suggest. Findings from the trial showed that a high, daily dose of simvastatin was safe, well tolerated, and slowed brain atrophy (shrinkage) by 43% over two years compared with placebo.

Results of a phase 2 study published in The Lancet suggest that simvastatin, a cheap cholesterol lowering drug, might be a potential treatment option for the secondary progressive, or chronic, stage of multiple sclerosis (MS), which is currently untreatable.
Credit: Aaron Chen / Fotolia

Results of a phase 2 study published in The Lancet suggest that simvastatin, a cheap cholesterol lowering drug, might be a potential treatment option for the secondary progressive, or chronic, stage of multiple sclerosis (MS), which is currently untreatable.

Related Articles


Findings from the MS-STAT trial showed that a high, daily dose of simvastatin was safe, well tolerated, and slowed brain atrophy (shrinkage) by 43% over two years compared with placebo. Longitudinal studies suggest that atrophy progression is linked with disability.

In its early stages, MS is characterized by intermittent neurological symptoms, called relapsing-remitting MS. Within 10 to 15 years, more than half of patients develop secondary progressive MS, a steady worsening of symptoms and increase in disability. To date, no licensed drugs have shown a convincing impact on this later stage of the disease.

Statins have been shown to have anti-inflammatory and neuroprotective effects on the nervous system. An initial clinical trial of simvastatin in people with early-stage MS showed reductions in brain lesions, suggesting an effect on the underlying disease process. But subsequent trials have had conflicting results.

To investigate the potential of simvastatin in the progressive stage of MS, the MS-STAT trial randomly assigned 140 people with secondary progressive MS (aged 18-65 years) to receive either 80 mg of simvastatin or placebo for 2 years.

"In the progressive stage of MS the brain shrinks by about 0.6% a year. Our main measure of success was to reduce the rate of brain atrophy," explains study leader Dr Jeremy Chataway of University College London Hospitals / UCL in the UK.

Analysis of pre-treatment and post-treatment brain MRI scans showed a reduction in the average atrophy rate to 0.3% a year with simvastatin, a 43% reduction (when adjusted for factors such as age and gender) compared with placebo. Additionally, small but significant improvements were noted in both a doctor (EDSS) and patient-reported (MSIS-29) disability scale. Simvastatin was generally well tolerated and serious adverse events were similar between the two groups (20% placebo vs 13% simvastatin).

According to Chataway, "Caution should be taken regarding over-interpretation of our brain imaging findings, because these might not necessarily translate into clinical benefit. However, our promising results warrant further investigation in larger phase 3 disability-driven trials." This clinical trial is the culmination of long-standing research led by Professor John Greenwood at the UCL Institute of Ophthalmology showing the potential therapeutic benefits of using statins to treat autoimmune diseases such as multiple sclerosis and uveitis. According to Professor Greenwood, "After nearly two decades of research, it is immensely gratifying to see this work progress into the clinic to deliver benefits to patients."

Writing in a linked Comment, Jacqueline Palace from the John Radcliffe Hospital, Oxford, UK and Neil Robertson from Cardiff University in Wales say, "Chataway and colleagues' study is a promising and novel development. The study is investigator led and has therefore focused on clinical need, targeting patients with progressive multiple sclerosis in whom most disability is incurred…The study also reports a predominant effect on neurodegenerative rather than inflammatory outcomes, suggesting a novel mechanism of action that might be suitable as combination treatment with immunomodulatory treatments…Further phase 3 studies to measure the effect of simvastatin on sustained disability, particularly in patients with non-relapsing secondary progressive and primary progressive multiple sclerosis, are clearly needed, but this trial represents a promising point from which to develop trials of progressive disease."


Story Source:

The above story is based on materials provided by The Lancet. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jeremy Chataway, Nadine Schuerer, Ali Alsanousi, Dennis Chan, David MacManus, Kelvin Hunter, Val Anderson, Charles R M Bangham, Shona Clegg, Casper Nielsen, Nick C Fox, David Wilkie, Jennifer M Nicholas, Virginia L Calder, John Greenwood, Chris Frost, Richard Nicholas. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. The Lancet, March 2014 DOI: 10.1016/S0140-6736(13)62242-4

Cite This Page:

The Lancet. "Statin may slow untreatable, progressive stage of multiple sclerosis." ScienceDaily. ScienceDaily, 18 March 2014. <www.sciencedaily.com/releases/2014/03/140318190031.htm>.
The Lancet. (2014, March 18). Statin may slow untreatable, progressive stage of multiple sclerosis. ScienceDaily. Retrieved November 25, 2014 from www.sciencedaily.com/releases/2014/03/140318190031.htm
The Lancet. "Statin may slow untreatable, progressive stage of multiple sclerosis." ScienceDaily. www.sciencedaily.com/releases/2014/03/140318190031.htm (accessed November 25, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, November 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com
Madagascar Working to Contain Plague Outbreak

Madagascar Working to Contain Plague Outbreak

AFP (Nov. 24, 2014) Madagascar said Monday it is trying to contain an outbreak of plague -- similar to the Black Death that swept Medieval Europe -- that has killed 40 people and is spreading to the capital Antananarivo. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com
Are Female Bosses More Likely To Be Depressed?

Are Female Bosses More Likely To Be Depressed?

Newsy (Nov. 24, 2014) A new study links greater authority with increased depressive symptoms among women in the workplace. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins